Nataki Douglas

Dr. Nataki Douglas

Department of Obstetrics, Gynecology and Women’s Health, Rutgers New Jersey Medical School, Newark, NJ, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2013 in Journal of Mammary Gland Biology and Neoplasia
Verified
Journal Article
Closed access
PDF file
NDNataki Douglas
Nataki Douglas
VPVirginia E. Papaioannou
Virginia E. Papaioannou

1 August 2009 in Endocrinology
Verified
Journal Article
Open access
PDF file
NDNataki Douglas
Nataki Douglas
HTHongyan Tang
Hongyan Tang
RGRaul Gomez
Raul Gomez
BPBronislaw Pytowski
Bronislaw Pytowski
DHDaniel J. Hicklin
Daniel J. Hicklin
RZRalf C. Zimmermann
Ralf C. Zimmermann
Implantation of an embryo induces rapid proliferation and differentiation of uterine stromal cells, forming a new structure, the decidua. One salient feature of decidua formation is a marked increase in maternal angiogenesis. Vascular endothelial growth factor (VEGF)-dependent pathways are active in the ovary, uterus, and embryo, and inactivation of VEGF function in any of these structures might prevent normal pregnancy development. We hypothesized that decidual angiogenesis is regulated by VEGF acting through specific VEGF receptors (VEGFRs). To test this hypothesis, we developed a murine pregnancy model in which systemic administration of a receptor-blocking antibody would act specifically on uterine angiogenesis and not on ovarian or embryonic angiogenesis. In our model, ovarian function was replaced with exogenous progesterone, and blocking antibodies were administered prior to embryonic expression of VEGFRs. After administration of a single dose of the anti-VEGFR-2 antibody during the peri-implantation period, no embryos were detected on embryonic d 10.5. The pregnancy was disrupted because of a significant reduction in decidual angiogenesis, which under physiological conditions peaks on embryonic d 5.5 and 6.5. Inactivation of VEGFR-3 reduced angiogenesis in the primary decidual zone, whereas administration of VEGFR-1 blocking antibodies had no effect. Pregnancy was not disrupted after administration of anti-VEGFR-3 or anti-VEGFR-1 antibodies. Thus, the VEGF/VEGFR-2 pathway plays a key role in the maintenance of early pregnancy through its regulation of peri-implantation angiogenesis in the uterine decidua. This newly formed decidual vasculature serves as the first exchange apparatus for the developing embryo until the placenta becomes functionally active.

1 April 2001 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NDNataki Douglas
Nataki Douglas
HJHarris Jacobs
Harris Jacobs
ABAlfred L. M. Bothwell
Alfred L. M. Bothwell
AHAdrian C. Hayday
Adrian C. Hayday

20 April 2010 in Cancer
Verified
Journal Article
Open access
PDF file
BYBo Yu
Bo Yu
NDNataki Douglas
Nataki Douglas
MFMichel J. Ferin
Michel J. Ferin
GNGary S. Nakhuda
Gary S. Nakhuda
KCKatherine Crew
Katherine Crew
DHDawn L. Hershman
Dawn L. Hershman
BACKGROUND: Premenopausal women undergoing chemotherapy are at risk for amenorrhea and impaired fertility. The objective of the current study was to assess levels of mullerian inhibitory substance (MIS), estradiol (E2), follicle‐stimulating hormone (FSH), and menstrual status, in women undergoing chemotherapy. METHODS: A nested prospective cohort study was conducted in women aged <40 years with breast cancer (BC) who were undergoing adjuvant chemotherapy (n = 26). Serum MIS, FSH, and E2 were measured before chemotherapy (baseline) and at Weeks 6, 12, 36, and 52. Controls were 134 age‐matched women with known fertility. Hormone levels were compared between the cases and controls at baseline. Differences between amenorrhea and age subgroups were tested using the nonparametric Wilcoxon 2‐sample test using a 2‐sided α of 0.05. RESULTS: Subjects with BC and age‐matched controls had similar baseline MIS levels (median, 0.94 ng/mL vs 0.86 ng/mL;, P > .05). Serum MIS decreased significantly at 6 weeks and remained suppressed for 52 weeks. E2 levels decreased, and FSH levels increased during chemotherapy; however, at 52 weeks, the levels returned to baseline. At 52 weeks, only 1 patient had MIS above the lower normal range, 15 had return of menstrual function, 11 had premenopausal levels of FSH, and 13 had follicular phase levels of E2. In women aged 35 years, 50% were amenorrheic. Amenorrheic and menstruating women were found to have similar MIS values at baseline and follow‐up. CONCLUSIONS: In young women with BC, chemotherapy decreases MIS rapidly and dramatically. Rapid reductions in MIS do not appear to be predictive of subsequent menstrual function. Ovarian reserve and endocrine function may be affected differently by chemotherapy. Cancer 2010. © 2010 American Cancer Society.

8 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
NMNoura Massri
Noura Massri
RLRachel Loia
Rachel Loia
Jenny L. SonesJenny L. Sones
Jenny L. Sones
RARipla Arora
Ripla Arora
NDNataki Douglas
Nataki Douglas
Uterine vascular remodeling is intrinsic to the cycling and early pregnant endometrium. Maternal regulatory factors such as ovarian hormones, VEGF, angiopoietins, Notch, and uterine natural killer cells significantly mediate these vascular changes. In the absence of pregnancy, changes in uterine vessel morphology and function correlate with different stages of the human menstrual cycle. During early pregnancy, vascular remodeling in rodents and humans results in decreased uterine vascular resistance and increased vascular permeability necessary for pregnancy success. Aberrations in these adaptive vascular processes contribute to increased risk of infertility, abnormal fetal growth, and/or preeclampsia. This Review comprehensively summarizes uterine vascular remodeling in the human menstrual cycle, and in the peri- and post-implantation stages in rodent species (mice and rats).

1 June 2009 in Fertility and Sterility
Verified
Journal Article
Closed access
MSMark V. Sauer
Mark V. Sauer
JWJeff G. Wang
Jeff G. Wang
NDNataki Douglas
Nataki Douglas
GNGary S. Nakhuda
Gary S. Nakhuda
PVPratibashri Vardhana
Pratibashri Vardhana
MGMichael M. Guarnaccia
Michael M. Guarnaccia